MicroPort<sup>®</sup> Gains its Fifth State Science and Technology Progress Award

Shanghai, China – On January 8, the project of "Key Technology Development and Large-scale Industrialization of Aortic Stent Graft Products", jointly developed by Shanghai MicroPort (Medical) Group Co., Ltd. ("MicroPort®"), its subsidiary MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular"), and Beijing Anzhen Hospital of Capital Medical University, won the second prize of State Science and Technology Progress Award. 
 
Aortic diseases are extremely dangerous, directly threatening or destroying the health of human beings, with up to 90% death rate once the aortic aneurysms rupture. People aged above 60 are considered high-risk group. Conventional operations in treating aortic diseases have high post-operative mortality. Nowadays there is a significant trend to treat these patients suffering aortic aneurysms with minimally invasive device technologies. 
 
The project of "Key Technology Development and Large-scale Industrialization of Aortic Stent Graft Products" was granted 30 patents, of which 24 are Chinese patents and six are international patents. In addition, it won the First Prize of Shanghai Science and Technology Progress Award in 2016. Up to date, products of the project have been used in top hospitals of around 30 provinces and cities in China, making the number of hospitals capable of performing aortic interventional treatment increase 20 folds from 25 to over 500, which creates large contribution to industry development. So far, products of the project have effectively treated 50,000 critically ill patients, with around 30% market share in China, the top among similar domestically made products. Meanwhile, their emergence forced imported products to reduce price by 40%, easing the burden for patients and saving healthcare resources for the government, with newly created direct economic benefits up to 370 million yuan in the past three years. In addition, the products have been exported to countries in Southeast Asia and Latin America, helping increase the awareness of Chinese brands and products.
 
Since its establishment in 1998, MicroPort® has become a leading interventional medical device provider in China. It promotes the development and popularization of interventional treatment as well as the development of inter-disciplines such as intelligent manufacturing, biological materials, and 3D printing. With over 200 products currently approved for use in over 5,000 hospitals worldwide, MicroPort® is contributing to a better world through its life-saving medical therapies and quality-improving care devices being used in patients every 15 seconds. In the future, MicroPort® will continue to strive for innovation to promote the development of independent brands and focus on creating a sound environment for innovation and an efficient mechanism to cultivate innovative talents, to provide patients with rapidly increasing high-end medical product offering pioneering in China and throughout the whole world.